公开(公告)号：US20240076318A1

公开(公告)日：2024-03-07

申请号：US18358350

申请日：2023-07-25

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Stefania CAPONE ,  Antonella FOLGORI ,  Armin LAHM ,  Benjamin WIZEL

IPC: C07K14/005 ,  A61K39/245 ,  C12N7/00

CPC classification number: C07K14/005 ,  A61K39/245 ,  C12N7/00 ,  A61K2039/70

Abstract: The invention provides Epstein-Barr Virus antigen polynucleotides, polypeptides and vectors; as well as immunogenic compositions comprising the same. It includes the use of Epstein-Barr Virus antigen constructs to produce vaccines for treating and preventing Epstein-Barr Virus infections and Epstein-Barr Virus-associated diseases, such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.

公开(公告)号：US20230158134A1

公开(公告)日：2023-05-25

申请号：US18075064

申请日：2022-12-05

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Stefano COLLOCA ,  Alessandra VITELLI ,  Benjamin WIZEL

IPC: A61K39/12 ,  A61K39/205 ,  C07K14/005 ,  C12N15/86 ,  A61K39/235 ,  C12N7/00

CPC classification number: A61K39/12 ,  A61K39/205 ,  C07K14/005 ,  C12N15/86 ,  A61K39/235 ,  C12N7/00 ,  A61P31/14

Abstract: The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.

公开(公告)号：US20210198321A1

公开(公告)日：2021-07-01

申请号：US16770963

申请日：2018-12-14

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Stefania CAPONE ,  Antonella FOLGORI ,  Armin LAHM ,  Benjamin WIZEL

IPC: C07K14/005 ,  C12N7/00 ,  A61K39/245

Abstract: The invention provides Epstein-Barr Virus antigen polynucleotides, polypeptides and vectors; as well as immunogenic compositions comprising the same. It includes the use of Epstein-Barr Virus antigen constructs to produce vaccines for treating and preventing Epstein-Barr Virus infections and Epstein-Barr Virus-associated diseases, such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.

公开(公告)号：US20220112245A2

公开(公告)日：2022-04-14

申请号：US16467569

申请日：2017-12-08

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Stefano COLLOCA ,  Alessandra VITELLI ,  Benjamin WIZEL

IPC: C07K14/005 ,  A61K39/39 ,  A61K39/205 ,  C12N15/86 ,  A61P31/14 ,  A61K39/21 ,  A61P31/18 ,  A61K39/12

Abstract: The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.

公开(公告)号：US20200172930A1

公开(公告)日：2020-06-04

申请号：US16631557

申请日：2018-07-19

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Benjamin WIZEL ,  Martine HARVEY ,  Lucile WARTER ,  Kate LUISI

IPC: C12N15/86 ,  A61K39/12

Abstract: The invention provides adenoviral vectors comprising transgenes encoding Chikungunya virus antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Chikungunya virus infections.